Sarah McBride, a former reporter at Bloomberg and the Wall Street Journal, is writing a book about memory and technology.
In 2004, cold turkey, my 63-year-old mother quit her estradiol patch, a treatment then commonly given to women to relieve menopause symptoms. It was two years after a landmark government report from the Women’s Health Initiative reported that similar hormone-replacement therapy — a combination of estrogen and progestin — raised the risk of breast cancer and heart disease. The group shut down that specific study three years early, and several months later reported yet more related negative side effects. My mom didn’t want to chance it.
The post A landmark health study was flawed. Did my mother pay the price? appeared first on Washington Post.
